Webb RP - Search Results

1

Structural Insights into Rational Design of Single-Domain Antibody-Based Antitoxins against Botulinum Neurotoxins.

Lam KH, Tremblay JM, Vazquez-Cintron E, Perry K, Ondeck C, Webb RP, McNutt PM, Shoemaker CB, Jin R. Lam KH, et al. Among authors: webb rp. Cell Rep. 2020 Feb 25;30(8):2526-2539.e6. doi: 10.1016/j.celrep.2020.01.107. Cell Rep. 2020. PMID: 32101733 Free PMC article.

2

Camelid VHH Antibodies that Neutralize Botulinum Neurotoxin Serotype E Intoxication or Protease Function.

Tremblay JM, Vazquez-Cintron E, Lam KH, Mukherjee J, Bedenice D, Ondeck CA, Conroy MT, Bodt SML, Winner BM, Webb RP, Ichtchenko K, Jin R, McNutt PM, Shoemaker CB. Tremblay JM, et al. Among authors: webb rp. Toxins (Basel). 2020 Sep 24;12(10):611. doi: 10.3390/toxins12100611. Toxins (Basel). 2020. PMID: 32987745 Free PMC article.

3

A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model.

Mukherjee J, Tremblay JM, Leysath CE, Ofori K, Baldwin K, Feng X, Bedenice D, Webb RP, Wright PM, Smith LA, Tzipori S, Shoemaker CB. Mukherjee J, et al. Among authors: webb rp. PLoS One. 2012;7(1):e29941. doi: 10.1371/journal.pone.0029941. Epub 2012 Jan 6. PLoS One. 2012. PMID: 22238680 Free PMC article.

4

Engineering of Botulinum Neurotoxins for Biomedical Applications.

Webb RP. Webb RP. Toxins (Basel). 2018 Jun 6;10(6):231. doi: 10.3390/toxins10060231. Toxins (Basel). 2018. PMID: 29882791 Free PMC article. Review.

5

Potency and stability of a trivalent, catalytically inactive vaccine against botulinum neurotoxin serotypes C, E and F (triCEF).

Webb R, Wright PM, Brown JL, Skerry JC, Guernieri RL, Smith TJ, Stawicki C, Smith LA. Webb R, et al. Toxicon. 2020 Mar;176:67-76. doi: 10.1016/j.toxicon.2020.02.001. Epub 2020 Feb 4. Toxicon. 2020. PMID: 32032587

6

Protection with recombinant Clostridium botulinum C1 and D binding domain subunit (Hc) vaccines against C and D neurotoxins.

Webb RP, Smith TJ, Wright PM, Montgomery VA, Meagher MM, Smith LA. Webb RP, et al. Vaccine. 2007 May 22;25(21):4273-82. doi: 10.1016/j.vaccine.2007.02.081. Epub 2007 Mar 16. Vaccine. 2007. PMID: 17395341

7

The C terminus of the catalytic domain of type A botulinum neurotoxin may facilitate product release from the active site.

Mizanur RM, Frasca V, Swaminathan S, Bavari S, Webb R, Smith LA, Ahmed SA. Mizanur RM, et al. J Biol Chem. 2013 Aug 16;288(33):24223-33. doi: 10.1074/jbc.M113.451286. Epub 2013 Jun 18. J Biol Chem. 2013. PMID: 23779108 Free PMC article.

8

A matrix-focused structure-activity and binding site flexibility study of quinolinol inhibitors of botulinum neurotoxin serotype A.

Harrell WA Jr, Vieira RC, Ensel SM, Montgomery V, Guernieri R, Eccard VS, Campbell Y, Roxas-Duncan V, Cardellina JH 2nd, Webb RP, Smith LA. Harrell WA Jr, et al. Among authors: webb rp. Bioorg Med Chem Lett. 2017 Feb 1;27(3):675-678. doi: 10.1016/j.bmcl.2016.11.019. Epub 2016 Nov 9. Bioorg Med Chem Lett. 2017. PMID: 28043798

9

Utilizing Ayurvedic literature for the identification of novel phytochemical inhibitors of botulinum neurotoxin A.

Yalamanchili C, Manda VK, Chittiboyina AG, Guernieri RL, Harrell WA Jr, Webb RP, Smith LA, Khan IA. Yalamanchili C, et al. Among authors: webb rp. J Ethnopharmacol. 2017 Feb 2;197:211-217. doi: 10.1016/j.jep.2016.07.069. Epub 2016 Jul 26. J Ethnopharmacol. 2017. PMID: 27469199

10

Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2, and A3.

Webb RP, Smith TJ, Wright P, Brown J, Smith LA. Webb RP, et al. Vaccine. 2009 Jul 16;27(33):4490-7. doi: 10.1016/j.vaccine.2009.05.030. Epub 2009 May 28. Vaccine. 2009. PMID: 19450643

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

47 results

Search Page